Effect of cytochrome P450 2C19 genotype on pharmacokinetics of vorivonazole in healthy volunteers:A systematic review and meta-analysis

VernacularTitle:细胞色素 P4502 C19基因多态性对健康受试者伏立康唑药代动力学影响的系统评价
Author: Xiao-Fei LI ¹ ; Cai-Yuan YU ; Yi CHENG ; Tian-Wei NIU ; Ken CHEN ; Hui-Lin TANG
Author Information

1. 北京大学第三医院药剂科
Keywords: voriconazole; cytochrome P450 2 C19; pharmacokinetic; gene polymorphism
From: The Chinese Journal of Clinical Pharmacology 2016;(3):267-269
CountryChina
Language:Chinese
Abstract: Objective To evaluate effect of cytochrome P450 2C19 ( CYP2 C19 ) genotype on pharmacokinetics of voriconazole in healthy volunteers. Methods Studies evaluating the CYP2C19 genetic polymorphism and pharmacokinetics of voriconazole were retrieved through a systematical search of electronic databases ( up to Feb.2015 ).Studies selection according to the inclusion criteria , data extraction and risk of bias assessment were conducted.The meta -analysis was performed using RevMan 5.0.Results Nine studies were included in this meta -analysis, 8 in English, 1 in Chinese.CYP2C19 gene polymorphism had a significantly effect on AUC , poor metabolizers ( PM)>intermediate metabolizers ( HEM ) >extensive metabolizers (EM) >ultrarapid metabolizers (UM), CL(EM>HEM>PM), Cmax ( PM >HEM, EM >UM ) , t1/2 ( PM >EM, PM >HEM ) and tmax ( PM>EM,HEM>EM).Conclusion The pharmacokinetics parameters of voriconazole were influenced significantly by CYP 2C19 genotype in healthy volunteers.